All In Biotech

Drug Trial Radar · NCT06938347

Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt

A Phase 3, Open-label, Multicenter, Randomized Crossover Trial Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Nov 5, 2025

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Agitated Solutions, Inc.Industry
Sponsor type
Industry
Collaborators
Bright Research Partners
First posted
Apr 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, multicenter, open-label, blinded, crossover trial in which each participant will undergo a randomized sequence of ASI-02 and agitated saline standard of care (SoC) via a saline contrast transthoracic echocardiogram (TTE) study.

Conditions

  • Right-To-Left Shunt

Interventions

  • Agitated Saline SoCDrug

    The recommended initial dose of agitated saline SoC is approximately 10 mL of saline containing approximately 1 mL of air, per institutional policy, rapidly mixed (approximately 10-20 presses) to manufacture microbubbles. No additives are allowed to the saline, including blood, dextrose, or bacteriostatic saline.

  • ASI-02Drug

    Each injection shall utilize one (1) ASI-02 product connected to one (1) pre-filled 10 mL 0.9% sodium chloride (saline) syringe. The ASI-02 investigational product will be connected to a standard luer lock connector and administered in its entirety. The intravenous bolus injected dose of ASI-02 is 9 mL of saline and 1 mL of air.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive percentage agreement (PPA) of ASI-02 for detecting right-to-left shunt versus agitated saline SoCTime frame: Procedure through 24- to 48-hour participant follow-up visit
  2. Negative percentage agreement (NPA) of ASI-02 for detecting right-to-left shunt versus agitated saline SoCTime frame: Procedure through 24- to 48-hour participant follow-up visit

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Northwestern University

    Chicago, Illinois · Recruiting

  • AH Illinois Masonic Center

    Chicago, Illinois · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • CentraCare

    Saint Cloud, Minnesota · Recruiting

  • Jackson Heart Clinic

    Jackson, Mississippi · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Aurora St. Lukes Medical Center

    Milwaukee, Wisconsin · Recruiting

  • Toronto General

    Toronto, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.